Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index - Carter, Lucy M; Gordon, Caroline; Yee, Chee Seng; Bruce, Ian; Isenberg, David; Skeoch, Sarah; Vital, Edward M (medRxiv, 2021)
Objective BILAG-2004 index is a comprehensive disease activity instrument for SLE but administrative burden and frequency of errors limits its use in routine practice. We aimed to develop a tool for more accurate, time-efficient scoring of BILAG-2004 index with full fidelity to the existing instrument.Methods Frequency of BILAG-2004 items was collated from a BILAG-biologics registry (BILAG-BR) dataset. Easy-BILAG prototypes were drafted to address known issues affecting speed and accuracy. After expert-verification, accuracy and usability of the finalised Easy-BILAG was validated against standard format BILAG-2004 index in a workbook exercise of 10 case vignettes. 33 professionals with a range of expertise from 14 UK centres completed the validation exercise.Results Easy-BILAG incorporates all items present in ≥5% BILAG-BR records, plus full constitutional and renal domains into a rapid single-page assessment. An embedded glossary and colour-coding assists scoring each domain. A second page captures rarer manifestations when needed. In the validation exercise, Easy-BILAG yielded higher median scoring accuracy (96.7%) than standard BILAG-2004 documentation (87.8%, p=0.001), with better inter-rater agreement. Easy-BILAG was completed faster (59.5min) than the standard format (80.0min, p=0.04) for 10 cases. An advantage in accuracy was observed with Easy-BILAG use among general hospital rheumatologists (91.3 vs 75.0, p=0.02), leading to equivalent accuracy as tertiary centre rheumatologists. Clinicians rated Easy-BILAG as intuitive, convenient, and well adapted for routine practice.Conclusion Easy-BILAG facilitates more rapid and accurate scoring of BILAG-2004 across all clinical settings which could improve patient care and biologics prescribing. Easy-BILAG should be adopted wherever BILAG-2004 assessment is required.Competing Interest StatementCaroline Gordon reports personal fees for honoraria from consultancy work from the Center for Disease Control and Prevention, AbbVie, Amgen, Astra-Zeneca, MGP, Sanofi and UCB, and personal fees for speakers bureau from UCB. David Isenberg has consulted for Astra Zeneca, Merck Serono, Eli Lilly, Servier and Genentech. The honoraria offered are passed onto a local arthritis charity. Sarah Skeoch reports speaker fees from Pfizer and grant income from Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement number 116106. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. Edward Vital has received research grants paid to his employer from AstraZeneca and Sandoz, and personal fees from Genentech, Aurinia, Lilly, AstraZeneca, ILTOO and Modus Therapeutics. Lucy Carter and Chee-Seng Yee declare no conflicts of interest. Funding StatementNo funding was obtained.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Easy-BILAG was registered as a multi-centre quality improvement initiative with Quality Assurance and Governance department of Leeds Teaching Hospitals NHS Trust and at the relevant governance departments at individual participating Trusts. No real-patient was used in Easy-BILAG validation material and specific research ethics approval was therefore not obtained. BILAG-BR is an ongoing prospective study with research ethics approval from NRES Committee North West, Greater Manchester West (REC: 09/H1014/64) and Health Research Authority approved on 9 November 2009 (IRAS ref. 24407).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data are available.